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Design and Development of Artificial Zinc Finger 
 Transcription Factors and Zinc Finger Nucleases 
to the hTERT Locus
Kimberly A Wilson1,2, Morgan L Chateau3 and Matthew H Porteus1,2,4
The ability to direct human telomerase reverse transcriptase (hTERT) expression through either genetic control or tunable 
regulatory factors would advance not only our understanding of the transcriptional regulation of this gene, but also potentially 
produce new strategies for addressing telomerase-associated disease. In this work, we describe the engineering of artificial 
zinc finger transcription factors (ZFTFs) and ZF nucleases (ZFNs) to target sequences within the hTERT promoter and exon-1. 
We were able to identify several active ZFTFs that demonstrate a broadly tunable response when screened by a cell-based 
transcriptional reporter assay. Using the same DNA-binding domains, we generated ZFNs that were screened in combinatorial 
pairs in cell-based extrachromosomal single-strand annealing (SSA) assays and in gene-targeting assays using stably 
integrated constructs. Selected ZFN pairs were tested for the ability to induce sequence changes in a Cel1 assay and we 
observed frequencies of genomic modification up to 18.7% at the endogenous hTERT locus. These screening strategies have 
pinpointed several ZFN pairs that may be useful in gene editing of the hTERT locus. Our work provides a foundation for using 
engineered ZF proteins (ZFPs) for modulation of the hTERT locus.
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Introduction
Telomeres are specialized chromosomal end caps comprised 
of 5′-TTAGGG-3′ hexanucleotide repeats which protect 
human chromosomes from genomic instability and replicative 
attrition which is a consequence of their linear structure and 
the inability of DNA polymerases to completely replicate chro-
mosomal ends.1 Telomerase extends and maintains telomere 
length, which allows a cell to keep proliferative capacity. Alter-
natively, the absence of active telomerase results in telomere 
shortening with every cell cycle.2 This becomes an important 
mechanism for cellular aging, lifespan, proliferative potential, 
and senescence. Telomere shortening is also an important 
tumor suppressive mechanism.3 The human telomerase 
holoenzyme is a complex of two components: hTR, a single-
stranded RNA template, and hTERT, a reverse transcriptase. 
As the limiting component, human telomerase reverse tran-
scriptase (hTERT) expression is constitutively repressed in 
normal somatic cell types.4 The expression of this gene can 
be upregulated to affect changes in proliferation potential, but 
this alone is insufficient to initiate oncogenesis.4–6
The promoter region controlling hTERT expression is 
densely composed of many regulatory elements. Many of 
these can be found within the first 300 basepairs (bp), which 
is considered to be the core promoter.7–9 Studies have sug-
gested that transcriptional regulation of hTERT is done 
in a cell context-dependent manner and the transcription 
factors controlling the promoter at different sites can vary 
between cell lines.7 Haploinsufficiencies and mutations in 
hTERT have also been implicated in a number of inherit-
able genetic diseases that result from increasingly shortened 
telomere lengths. These diseases (such as idiopathic pulmo-
nary fibrosis, aplastic anemia, and dyskeratosis congenita) 
exhibit attrition of fast-growing tissues, stem cell depletion, 
and present at earlier ages in each successive genera-
tion (anticipation).10–12 The ability to modify the promoter of 
hTERT, therefore, would have a wide range of research and 
potentially therapeutic applications. In addition, systematic 
site-specific mutational analysis of the endogenous hTERT 
locus or the use of a tunable regulatory factor at the hTERT 
promoter across many human cell lines would yield useful 
insights about the regulation of this crucial gene.
Artificial zinc finger transcription factors (ZFTFs) and ZF 
nucleases (ZFNs) are methods to modulate the activity of 
specific genes. Both chimeric proteins are based on the well-
characterized ZF DNA-binding protein domains (ZFPs). The 
polydactyl ZFP is custom engineered for a chosen target site 
and are commonly generated through one of four publicly 
available methods: (i) combining individual ZFs in a modular 
fashion, (ii) using randomly recombined libraries of ZFs in 
the bacterial-2-hybrid (B2H) selection-based OPEN platform, 
(iii) context-dependent assembly, or (iv) a hybrid methodol-
ogy that incorporates elements of both.13–17 A novel, chimeric 
protein with site-specific activity is then made by attaching 
another functional effector domain to the ZFP.
ZFPs, when linked to a transcriptional effector domain, 
become ZFTFs that will recruit the cellular machinery nec-
essary to activate or repress transcription and are typically 
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developed to sequences found in the promoter regions of 
the target gene. Due to the ability of a ZFTF to site specifi-
cally regulate transcription in cell culture and in vivo, these 
artificial proteins are useful tools for drug development.18,19 
Recently, Sohn et al. (2010) developed a set of four-fingered 
ZFTFs that target sequences within the hTERT core pro-
moter and demonstrated transcriptional repression of hTERT 
in HEK293 cells by linking the KRAB repressor domain to 
ZFPs made by modular assembly.20 Several ZFTFs have 
also been successfully made to other target genes such as 
ErbB-2, VEGF, and utrophin, all of which have therapeutic 
potential.21–23
ZFNs are made by joining a ZFP to the nuclease domain 
of the FokI endonuclease and are developed in pairs to 
“full target sites” of the general structure: 5′-(ZFN target 
site 1)-spacer-(ZFN target site 2)-3′.24,25 The binding of the 
two ZFNs at the cognate target half-sites allows the nuclease 
domain to dimerize in the spacer region and create a DNA 
double-stranded break (DSB).26 If the DSB is repaired by 
homologous recombination using an exogenously supplied 
donor DNA fragment, then the ZFN-targeted locus can be 
edited to introduce any number of modifications from single 
point mutations to the installment of large transgenes. Repair 
of the DSB through error-prone pathways (e.g., non-homol-
ogous end joining) can also result in changes to the nucleo-
tide content of the target site.27,28 ZFNs have been used to 
perform genomic editing in human cells and are currently 
undergoing rapid development for gene therapy and clinical 
trials using ZFNs directed against the CCR5 gene that have 
already been initiated.29–31
In this study, we report on the progress towards engineer-
ing new ZFTFs for transcriptional activation and ZFNs that 
target the hTERT locus. We have identified five ZFN full 
sites (10 target half-sites total) within the hTERT promoter 
and exon-1. Multiple three-fingered ZFPs were generated for 
each target half-site using the OPEN platform strictly for eight 
target half-sites and a hybrid methodology that incorporated 
module fingers at the Finger 1 or Finger 2 positions in the 
OPEN protocols for the other two target half-sites. The result-
ing ZFPs were converted into ZFTFs or ZFNs by linking these 
DNA-binding domains to either a VP16 transactivator domain 
or a nuclease, respectively. ZFTFs were screened for the 
ability to upregulate transcriptional activity through cotrans-
fection with an episomal hTERT promoter-driven green fluo-
rescent protein (GFP) reporter construct in HEK293 cells. 
We found that the ZFTFs could not only induce GFP expres-
sion in a coarsely tunable manner, but could also be used in 
combination. ZFN versions of many of the same ZFPs used 
as ZFTFs were screened and assayed using a extrachrom-
somal single-strand annealing (SSA) assays, a chromosom-
ally integrated GFP gene-targeting reporter assay, and a 




name Sequence Starta End
hTERT5 5′-AGCCACTACcgcgaGGTGCTGCC-3′ 46 68
hTERT5L 5′-GTAGTGGCT-3′ 46 54
hTERT5R 5′-GGTGCTGCC-3′ 60 68
hTERT5C 5′-CACTACCGCgaggtGCTGCCGCT-3′ 49 71
hTERT5CL 5′-GCGGTAGTG-3′ 49 57
hTERT5CR 5′-GCTGCCGCT-3′ 63 71
hTERT5S 5′-CCCGCCCTCtcctcGCGGCGCGA-3′ −85 −63
hTERT5SL 5′-GAGGGCGGG-3′ −85 −77
hTERT5SR 5′-GCGGCGCGA-3′ −71 −63
hTERT6 5′-CCCGGCCACccccgcGATGCCGCG-3′ −16 8
hTERT6L 5′-GTGGCCGGG-3′ −16 −8
hTERT6R 5′-GATGCCGCG-3′ −1 8
hTERT6B 5′-GCCAGCGGCcaaaggGTCGCCGCA-3′ −507 −484
hTERT6BL 5′-GCCGCTGGC-3′ −507 −499
hTERT6BR 5′-GTCGCCGCA-3′ −492 −484
hTERT, human telomerase reverse transcriptase.


















Figure 1 Approximate location and sequence of the human telomerase reverse transcriptase 5 (hTERT5) and hTERT6 sites in 
the hTERT locus. (a) The hTERT5 and hTERT6 zinc finger nuclease (ZFN) full target sites were identified in the hTERT promoter and 
exon-1. Genomic sequences are provided in the traditional 5′-3′ orientation of the top strand and 3′-5′ of the bottom strand with position is 
given relative to the translational start codon. (b) Schematic of hTERT promoter locus showing relative position of hTERT6L, hTERT6R, 
and hTERT5R zinc finger transcription factor-binding sites at scale. The arrow represents the site of the initiation ATG.
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Cel-I mutagenesis assay on the endogenous site. Our results 
present promising data towards developing new tools for not 
only studying the hTERT locus, but also creating new meth-
ods for treating telomerase-associated genetic disease.
Results
In our search for suitable target sites, we chose to limit our 
focus to the hTERT core promoter and exon-1 sequences for 
several reasons. First, these sequences are a very GC-rich 
region and as such are likely to have multiple high probability 
ZFP-binding sites.14,15 Second, this part of the hTERT locus 
is thought to be where the majority of the transcriptional con-
trol occurs and contains a high density of both known and 
putative regulatory sequences. Finally, for ZFN applications, 
higher rates of gene conversion are possible if a DSB is deliv-
ered in close proximity to the desired site of change.32,33 Thus, 
if gene editing to the core promoter or 5′-coding regions were 
to be accomplished, then it would be an advantage to engi-
neer ZFNs to target sites within those sequences.
We identified five full ZFN target sites (10 target half-sites 
total) either within or in proximity to the hTERT core promoter 
and exon-1, which are listed in Table 1. All target half-sites in 
the chosen full ZFN target sites follow the 5′-GNNGNNGNN-3′ 
sequence motif, except for the hTERT5SR target half-site, 
which contains a CNN triplet. Furthermore, the hTERT5 and 
hTERT5C target sites overlap as a 3 bp frame shift of one 
another. For the remainder of this report, we will narrow our 
scope to the hTERT5 and hTERT6 target sites and data gen-
erated at all other sites can be found in the Supplementary 
Tables S1–4. The hTERT5R and hTERT6L target half-sites 
have been targeted previously but the full target sites we 
describe here have not.20,34 Both the hTERT5 and hTERT6 
target sites are located in exon-1 of the hTERT locus with the 
hTERT6 site containing the translational start codon within 
the hTERT6R target half-site (Figure 1).
Engineering ZFPs by modular assembly and OPEN 
methods
In order to create three-fingered ZFPs for the 10 target half-
sites, we utilized three different methods. First, we used the 
B2H-based OPEN protocols to generate candidate DNA-
binding domains for eight of the target half-sites, includ-
ing those for hTERT5 and hTERT6 full sites (Table 2 and 
Supplementary Table S1). Next, for the hTERT5SL and 
hTERT5SR half-sites, we installed a module finger (Addgene; 
http://www.addgene.org) in place of one of the ZFs within the 
three-fingered rZF libraries used in the OPEN selections due 
to the lack of coverage provided for some GNN35 and CNN 
sequences.36 We have successfully done this previously in 
making ZFPs to the GFP gene37 (Supplementary Table S1). 
In addition to those ZFPs generated through OPEN proto-
cols for hTERT6L and hTERT6R target half-sites, we con-
structed ZFPs made by modular assembly (Table 2). Thus, 
we were able to generate multiple candidate ZFPs for each 
target half-site. Although there is a high degree of conserva-
tion of the residues that mediate sequence recognition, there 
is also significant variation of the other residues. Since there 
is a component of context-dependence to DNA binding, we 
Table 2 Zinc finger DNA-binding domains generated in this study for the 
hTERT5 and hTERT6 target sites
hTERT5L GTA GTG GCT
Method Finger 3a Finger 2 Finger 1 ZFTF ZFN
OPEN QSPSLNR RREVLMN NAHQLKR — pKW741
OPEN QSTSLQR RHEVLVN GRQALDR — pKW744b
OPEN QKVSLKR RKQVLTN QRQALDR — pKW745
OPEN QIVSLRR RIEILRN NGQGLRR — pKW746
hTERT5R GGT GCT GCC
Method Finger 3 Finger 2 Finger 1 ZFTF ZFN
OPEN QNHGLLR LSQTLKR DRRTLDR pKW639 pKW663
OPEN LMHQLNR LSQTLKR DGGTLHR pKW640 pKW664b
OPEN QNHGLLR LSQTLKR DSSTLAR — pKW665
OPEN LMHGLVR LSQTLKR DSSTLAR pKW641c —
OPEN HRHGLGR LSQTLKR DSTTLRR pKW642 pKW666
OPEN LMHGLVR LSQTLKR DRRTLDR pKW643 —
OPEN VMHHLAR LSQTLKR DRRTLDR pKW644 —
OPEN LMHGLVR LSQTLKR ERRGLDR pKW645 —
OPEN LMHGLVR LSQTLKR DGRGLER pKW646 —
hTERT6L GTG GCC GGG
Method Finger 3 Finger 2 Finger 1 ZFTF ZFN
Modular RSDALTR DRSDLTR RSDHLSR pKW308 —
OPEN RADALTR DSSVLRR RREKLRI pKW616 —
OPEN RADSLTR DRSVLVR RQDHLAR — pKW632
OPEN RRDALLR DTSVLNR KQDHLNR pKW618 pKW633
OPEN RRDLATR DRSVLAR KKDHLDR pKW619 pKW634
OPEN RADSLTR DVSVLKR ARDKLVR pKW620c pKW635b
OPEN RVDALTR DVSVLKR KQDHLAR pKW621 pKW637
OPEN RRDALTR DTSVLTR RREQLGR pKW622 pKW638
OPEN RGDSLTR DTSVLNR RKEKLRI pKW623 —
hTERT6R GAT GCC GCG
Method Finger 3 Finger 2 Finger 1 ZFTF ZFN
Modular QSSNLAR DRSDLTR RSDDLTR pKW309 —
OPEN VRSNLGR DRSVLRR RQHSLRR pKW599 pKW609
OPEN VTHNLNR DTSVLNR RRHNLDR pKW598 pKW608
OPEN LTHNLRR DRTTLKR TQHNLDR pKW600 —
OPEN LTHNLRR DPTVLKR TTHNLKR pKW601 pKW611
OPEN LTHNLRR ESTTLHR RQHSLRR pKW602c —
OPEN LSGNLRR DRTTLHR RTHSLAR pKW603 pKW613b
GFP1 GAA GAT GGT
Method Finger 3 Finger 2 Finger 1 ZFTF ZFN
OPEN37 QHPNLTR VAHNLTR TRQKLGV —
GFP-
ZFN1d
GFP2 GAC GAC GGC
Method Finger 3 Finger 2e Finger 1 ZFTF ZFN
OPEN37 EGGNLMR DRSNLTR APSKLDR —
GFP-
ZFN2d
GFP, green fluorescent protein; hTERT, human telomerase reverse 
transcriptase; ZFN, zinc finger nuclease; ZFTF, zinc finger transcription factor.
aAmino acid sequences of individual zinc fingers are given in the −1 to 
+6 positional order of the α-helix. bIdentified as highly active zinc finger 
nucleases in Cel1 assays, see Figure 6. cIdentified as highly active zinc 
finger transcription factors. dPreviously characterized zinc finger nucleases 
used as a positive control. eModular zinc finger used.
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screened variants for their activity. These results present a 
unique set of custom engineered, three-fingered ZFPs for the 
hTERT locus.
hTERT ZFTFs activate gene expression through hTERT 
promoter sequences
We converted many of the ZFPs for the hTERT5R, hTERT6L, 
and hTERT6R target half-sites into ZFTFs (23 total) by link-
ing the VP16 transcriptional activation domain to the N-termi-
nus of the candidate ZFP (Table 2).38 We tested the activity of 
these ZFTFs using an extrachromosomal GFP reporter sys-
tem. In this system, ~3 kb of the hTERT promoter and exon-1 
were cloned upstream of a GFP reporter gene (pMC6). We 
hypothesized that the candidate ZFTF would bind to the 
 cognate target site within this sequence and recruit the tran-
scriptional machinery necessary to drive GFP expression 
(Figure 2a). We cotransfected the ZFTF-expressing plasmids 
and pMC6 into HEK293 cells (an hTERT+ cell line) and mea-
sured the changes in %GFP+ populations by flow cytometry 
to assess the efficacy of these ZFTFs (Figure 2b). We found 
that all of the ZFTFs acted as artificial transcription factors 
and increased the number of GFP+ cells in these populations, 
in some instances, the fold stimulation could be as high as 
~35-fold or greater (Figure 2c).
In our screen of all ZFTFs made, we found that stimulation 
of GFP expression could vary significantly between individual 
ZFTFs (Figure 2c). Overall, the ZFTFs made with ZFPs from 
the OPEN platform performed better than those made purely 
by modular assembly, with few exceptions.17 These results 
support the idea that even though the major contact residues 
are conserved, that the non-contact residues are still impor-
tant in determining the overall activity of the protein (Table 2).
Of the 23 ZFTFs screened, we chose the best performing 




































































































































Figure 2 Screening human telomerase reverse transcriptase (hTERT) zinc finger transcription factors (ZFTFs) for transcriptional 
activation activity. (a) Schematic of the pMC6 transcriptional reporter, which contains 3 kb of the hTERT promoter and exon-1 sequence 
upstream of a green fluorescent protein (GFP) reporter gene. When cotransfected with a ZFTF-expressing plasmid, the ZFTF will bind 
to the pMC6 reporter plasmid and recruit the cellular machinery necessary to express GFP. (b) Flow cytometry plots demonstrating the 
increase in GFP+ cells after cotransfection of 100 ng of the MC6 reporter plasmid with 700 ng of plasmid expressing the KW602 ZFTF in 
HEK293 cells. Here, the x-axis plots cellular autofluorescence as “orange” (abscissa) and the y-axis plots the fluorescent intensity of GFP 
expressed by pMC6 as “green”. (c) All ZFTFs listed in Table 2 were screened for transcriptional activation activity using pMC6. Our results 
identify which ZFPs efficiently recognize and bind the hTERT target half-sites as ZFTFs to stimulate increases in %GFP+ over background 
(mean ± SD). ZFP, zinc finger protein.
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KW641) and tested them for a potential dose response. We 
cotransfected single ZFTFs in increasing amounts with the 
pMC6 reporter plasmid and found that as more ZFTF was 
transfected, more GFP expression was generated (Figure 3). 
We also tested whether combinations of ZFTFs could stimu-
late transcriptional activity and found that the individual ZFTFs 
did not interfere with each other. With the combinations, we 
found an additive response for different ZFTFs (Figure 3). This 
data reinforces previous findings demonstrating that ZFTFs 
can elicit a tunable response from a target gene and suggests 
that this may be possible for the hTERT locus as well.22,39
hTERT ZFNs can initiate repair of an extrachromosomal 
GFP reporter by SSA
To further test the ZFPs engineered to site specifically tar-
get the hTERT locus, we converted a total of 39 ZFPs into 
ZFNs by installing a wild-type (but not codon-optimized) 
FokI endonuclease domain (Fn) to the C-terminus of the 
ZFP (Table 2 and Supplementary Table S1). Due to varia-
tions in activity seen in the ZFTFs and individual deviations 
from the consensus sequence in multiple ZFPs, we again 
designed a screening strategy to test pairing of ZFNs in a 
combinatorial manner for each target site. To determine the 
ability of a ZFN pair to recognize, bind, and cut the desired 
target sequence, we constructed four GFP-based g (SSA 
assay reporter plasmids where a full hTERT ZFN target site 
would be inserted between two repeated sequences within 
the GFP gene. The inserted ZFN target sites also include 
the full GFP1/2 site, which can be targeted by the GFP-
ZFN1 and GFP-ZFN2 ZFN pair as a positive control and 
internal standard. In this assay, a GFP-based SSA reporter 
plasmid is cotransfected with ZFN-expressing plasmids 
together into HEK293 cells. After delivery of the ZFN-medi-
ated DSB, the 5′ overhangs anneal together at the site of 
the repeats in the GFP gene. When repaired by the endog-
enous cellular SSA repair pathway, functionality is restored 
to the GFP reporter construct and GFP+ cells are detected 
by flow cytometry (Figure 4). We report rates of GFP gene 
repair by hTERT ZFN activity as a relative percentage of 
the nuclease activity measured for the GFP-ZFN1/2 internal 
standard and positive control (Tables 3 and 4; Supplemen-
tary Tables S2–4).37
After screening all five combinatorial sets of pairings, we 
found that the hTERT5 and hTERT6 ZFN sets were, broadly, 
the most active sets of ZFNs (Tables 3 and 4). For the ZFNs 
developed for the hTERT5 target site, the KW744/KW664 
ZFN pairing exhibited equal nuclease activity to the GFP-
ZFN1/2–positive control pair. Also, 8 out of 16 possible pair-
ings were shown to have >50% activity relative to the control 
(Table 3). The hTERT6 ZFN set produced the most active 
nucleases out of those tested. In this combinatorial screen, 
the KW633/KW609 hTERT6 ZFN pair was more active than 
the GFP-ZFN1/2 standard by threefold. We also observed 
that all but six pairs demonstrated nuclease activity that was 
higher than the GFP-ZFN1/2 standard (Table 4). Therefore, 
using the SSA assay we identified a number of highly active 
ZFN pairs targeting the hTERT sequences.
Gene targeting by the hTERT6 ZFNs at a chromosomally 
integrated GFP reporter construct
We further studied the hTERT6 ZFNs using a chromosom-
ally integrated GFP reporter system. Based on a previ-
ously described system, we designed another GFP-based 
reporter construct that was rendered non-functional through 
the insertion of an hTERT full ZFN target site and an I-SceI 
homing endonuclease recognition site as an internal stan-
dard.24 This insertion does not disrupt the endogenous 
GFP1/2 target site that can be found in the GFP gene and 






















Figure 3 Human telomerase reverse transcriptase (hTERT) 
zinc finger transcription factors (ZFTFs) exhibit an additive 
response. The best performing ZFTF for each target half-site were 
transfected in increasing amounts of ZFTF-expressing plasmid 
(200, 400, and 600 ng) with 100 ng of pMC6 into HEK293 cells. 
The KW602, KW620, and KW641 ZFTFs were also cotransfected 
in pairs or all three combined (200 ng each, mean ± SD).
GFP1/2 site - hTERT L/R site
ZFN1 protein ZFN2 protein




Figure 4 Diagram of the green fluorescent protein (GFP)-
based single-strand annealing (SSA) assay. For the purpose 
of screening nuclease activities of various zinc finger nuclease 
(ZFN) pairs, we inserted the GFP1/2 ZFN full site and a human 
telomerase reverse trancriptase (hTERT) ZFN full site between 
two repeated sequences (hatch boxes) within a GFP reporter 
gene. Cotransfection of this reporter plasmid (20 ng) with ZFN-
expressing plasmids (100 ng each) into HEK293 cells results in 
the delivery of a double-stranded break between the repeated 
GFP sequences which is then repaired by the endogenous SSA 
pathway (after the repeat sequences have annealed to each other) 
to produce a functional GFP reporter gene.
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this assay (Figure 5). Briefly, we generated a transgenic 
HEK293 cell line containing the stably integrated reporter 
construct and cotransfected the ZFN-expressing plasmids 
in pairs along with a donor plasmid. Function of the GFP 
gene is restored if the ZFNs cut their cognate target site and 
stimulated homologous recombination-mediated repair with 
the donor plasmid. Again, ZFN activity is normalized as a 
relative percentage of the activity measured for the internal 
standard, I-SceI (Table 5).
In repeating the hTERT6 ZFN combinatorial pairing 
screen, we found that all hTERT6 ZFN pairs stimulated 
less gene targeting than the GFP-ZFN1/2–positive control. 
The best performing pair, KW635/KW613, produced ~40% 
activity relative to I-SceI (Table 5). We again observed that, 
in general, the ZFNs made from ZFPs with purely module 
fingers showed low activity in this screen when compared 
with nucleases from ZFPs made by OPEN methodologies.17 
The KW610 ZFN, made from the same ZFP used to make 
the KW600 ZFTF, produced no evidence of nuclease activity 
in this gene-targeting assay even though we observed mea-
surable activity in the SSA assay screens. Despite all other 
hTERT6 ZFN pairs showing higher activity in the SSA activity 
than the GFP-ZFN1/2 pair, in this chromosomal-based assay, 
the hTERT6 ZFNs did not have as much activity as the GFP-
ZFN1/2 pair. A reason for this discrepancy is that a chromo-
somal gene-targeting assay is a more stringent screen than 
an extrachromosomal SSA assay. Using the chromosomal 
GFP-based reporter, we were able to narrow the candidate 
ZFNs to be tested for activity at the endogenous hTERT 
locus.
ZFN-induced genomic modification at the hTERT locus
Future development of these ZFNs for gene targeting 
requires demonstrating efficacy for ZFN-mediated genomic 
modification at the endogenous hTERT locus. We chose the 
hTERT5 KW744/KW664 and hTERT6 KW635/KW613 ZFNs 
because they exhibited the best activity in our screening 
assays. To assay for genomic modification, we transfected 
the ZFN pairs into K562 cells and measured the rates of 
imperfect DSB repair by non-homologous end joining at 
the endogenous genomic locus using the Cel-I assay.40 We 
found that the hTERT5 ZFNs gave ~19% allele modification 
activity and the hTERT6 ZFNs gave ~7% allele modification 
activity (Figure 6). For both sets of ZFNs, using a codon-opti-
mized nuclease domain was critical to obtain maximal activ-
ity. While our screening assays suggested that the hTERT6 
ZFNs would have greater activity than the hTERT5 ZFNs, 
we found that the reverse was true in K562 cells. The SSA 
assay may not be predictive as it is a transient transfection 
assay in with the reporter plasmid is extrachromosomal and 
present in multiple copies. Similarly, the assay for the ZFTFs 
Table 3 Combinatorial screen of hTERT5 ZFN pairs in the SSA assay
GFP-ZFN2 KW663 KW664 KW665 KW666
GFP-ZFN1 100%a — — — —
KW741 — 57 61 63 64
KW744 — 75 104 78 67
KW745 — 37 32 13 24
KW746 — 33 34 25 30
GFP, green fluorescent protein; hTERT, human telomerase reverse 
transcriptase; SSA assay, single-strand annealing assay; ZFN, zinc finger 
nuclease.
aAll hTERT ZFN pair activity is normalized as a mean percentage of the GFP-
ZFN1/2 positive control pair (set to 100%).
Table 4 Combinatorial screen of hTERT6 ZFN pairs in the SSA assay
GFP-ZFN2 KW608 KW609 KW610 KW611 KW613
GFP-ZFN1 100%a — — — — —
KW632 — 106 194 59 166 122
KW633 — 281 298 35 255 208
KW634 — 228 203 12 183 142
KW635 — 239 171 46 231 195
KW637 — 281 238 15 238 223
KW638 — 236 280 22 280 226
GFP, green fluorescent protein; hTERT, human telomerase reverse 
transcriptase; SSA assay, single-strand annealing assay; ZFN, zinc finger 
nuclease.
aAll hTERT ZFN pair activity is normalized as a mean percentage of the GFP-






Stably integrated non-functional GFP construct
Functional GFP reporter construct
ZFN1 protein ZFN2 protein
ZFN 1 ZFN 2
1) Cotransfection of repair donor
    and ZFN expression plasmids
2) ZFNs deliver DSB to target
    site within the GFP construct
3) DSB is repaired by HR using 
    repair donor
STOP - I-SceI site - +1 - hTERT L/R site
GFP
Figure 5 Schematic of the green fluorescent protein (GFP)-
based gene-targeting reporter cell line. Based on a previously 
described strategy, we rendered a GFP reporter gene non-functional 
through the insertion of a stop codon, an I-SceI recognition site, 
a frame shift nucleotide, and the human telomerase reverse 
transcriptase 6 (hTERT6) zinc finger nuclease (ZFN) full site. Using 
this construct, we generated a stably integrated clonal HEK293 cell 
line in which we cotransfected pairs of ZFN-expressing plasmids 
and a repair donor plasmid. Nuclease activity of the ZFN pair is 
measured by the ZFN-mediated HR repair event between the cut 
GFP reporter and the donor plasmid producing a functional GFP 
reporter gene. The CAG promoter used in these experiments is a 
hybrid of the CMV intermediate-early enhancer and the chicken 
β-actin promoter. CMV, cytomegalovirus; DSB, double-stranded 
break; HR, homologous recombination.
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is also a transient extrachromosomal reporter assay and 
subject to the same limitations. In addition, further sources 
of discrepancy include: (i) that the hTERT6 ZFNs have more 
toxicity than the hTERT5 ZFNs (data not shown); (ii) that the 
chromatin differences of the target sites at the endogenous 
promoter in K562 cells is modulating the activity of the ZFNs; 
or (iii) that endogenous transcription or regulatory factor 
binding to the promoter is competing with ZFN binding.7 In 
sum, we have demonstrated that both pairs of ZFNs have the 
potential to be used as tools in generating cell lines with spe-
cific hTERT gene modifications, but additional studies will be 
necessary to show this.
Discussion
Due to the role hTERT plays in telomere regulation, the 
hTERT locus is an important target for research and drug 
development.41 The ability to direct hTERT transcription in 
a dose-dependent manner or edit the nucleotide content 
of the locus could yield useful insights into the regulation 
of this gene, cellular aging, and the oncogenic process. To 
this end, we have developed many ZFPs that recognize 
sequences within the hTERT promoter and exon-1 (Table 1 
and Figure  1). We built the ZFPs using modular assem-
bly methods, the B2H-based OPEN platform, and a hybrid 
method that combines the two protocols.14,15 This resulted in 
several candidate ZFPs for every target half-site.42 Therefore, 
we used several different screens to identify the most appro-
priate ZFP that has the ability to recognize and direct activ-
ity to the cognate target site, whether as a ZFTF or a ZFN 
(Table 2 and  Supplementary Table S1).
As ZFTFs, we were able to demonstrate that many of our 
ZFPs linked to the VP16 effector domain could stimulate 
the transcription of an hTERT promoter exon-1–driven GFP 
reporter gene (Figure 2). We were also able to demonstrate 
that ZFTFs developed for sites in the hTERT locus could 
elicit transcriptional activation in coarsely tunable manner in 
which incremental increases in ZFTF produced an additive 
response from the GFP-based reporter (Figure 3). This is 
consistent with the findings of others using ZFTFs at other 
gene targets.22,39 Our ZFTF screen also identifies some well-
performing candidate ZFTFs (e.g., KW602, KW620, and 
KW641) that may be pursued for future research in endog-
enous hTERT transcriptional regulation. In comparison to the 
ZFTFs made by modular assembly described in Sohn et al. 
(2010), which were demonstrated to be effective repressors 
of hTERT transcription, we found the KW308 and KW309 
modular assembly ZFTFs to be less effective at activating 
transcription than the OPEN-generated ZFTFs.13,17,20 The dif-
ferences in efficacy for modular assembly ZFPs as ZFTFs 
may be due to the differences in the module fingers used to 
construct the ZFPs, the effector domains, and design of the 
reporter assays.
To test the candidate ZFPs as nucleases, we screened 
sets of ZFN pairs in a combinatorial fashion for each hTERT 
target site identified using a GFP-based SSA assay (all 
sites) and a chromosomally integrated GFP gene-targeting 
assay (hTERT6 only) (Figure 4). ZFNs to the hTERT5 and 
hTERT6 site were the most active sets of nucleases in the 
SSA assays (Tables 3 and 4; Supplementary Tables S2–4). 
We then selected two ZFN pairs to demonstrate mutation 
of the endogenous genomic sequence and were able to 
achieve modification frequencies up to 18.7% (Figure 6). As 
a result, we have not only successfully custom-engineered 
ZFPs to sequences found in the hTERT promoter and exon-1 
region, but have also shown that, as ZFNs, these artificial 
proteins can direct activity to the cognate target site within 
the genomic locus.
In summary, the data generated by our screening strate-
gies provide the necessary results to move forward with using 
these ZFTFs and ZFNs as potential tools to modulate hTERT 
expression and edit the genomic locus for both research and 
clinical applications.
%Modified:
hTERT site: Uncut 6
0 7 19 4 4




Figure 6 Zinc finger nuclease (ZFN)-induced modification 
of the genomic human telomerase reverse transcriptase 
(hTERT) locus in K562 cells. ZFN-treated cell populations were 
treated with either the hTERT5 (KW744/KW664) or hTERT6 
ZFNs (KW635/KW613) and screened in bulk for mutations 
in the genomic that arose after repair of the ZFN-induced 
double-stranded break by NHEJ pathways. Mismatches in the 
mutated sequences are detectable by digestion with a form of 
the Cel1 nuclease (Surveyor). We included the use of human 
codon-optimized Fn domains in the ZFNs and expected digest 
products are given to the right of the figure. NHEJ pathway, non-
homologous end joining pathway.
Table 5 Combinatorial screen of hTERT6 ZFN pairs in the gene-targeting 
assay




KW98 0 5 (1) 6 (5) 0 2 (1) 2 (2)
KW632 0 28 (16) 18 (17) 0 13 (6) 11 (4)
KW633 0 8 (3) 15 (7) 0 34 (12) 27 (9)
KW634 1 (1) 16 (8) 4 (2) 0 19 (6) 10 (3)
KW635 0 28 (15) 16 (2) 0 21 (2) 42 (17)
KW637 0 19 (5) 18 (11) 0 22 (8) 30 (15)
KW638 0 36 (19) 12 (4) 0 35 (15) 27 (11)
GFP, green fluorescent protein; hTERT, human telomerase reverse 
transcriptase; ZFN, zinc finger nuclease.
aZFN-mediated repair of the mutated GFP sequence by homologous 
recombination results in measurable changes in GFP expression in treated 
cells as read by flow cytometry. Rates of gene conversion for all hTERT ZFN 
pair activity was normalized as a relative percentage of the nuclease activity 
measured for the internal I-SceI standard, set to 100% (mean (SEM), N = 3). 
On average, there were 32,315 ISce-I generated repair events per million 
cells treated.
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Generating ZF DNA-binding domains to target sites at the 
hTERT locus. Five full ZFN target sites were identified in the 
hTERT core promoter and exon-1 and are listed in Table 1. 
We used the publically available OPEN platform and pro-
tein backbone sequence to construct three-fingered ZFP 
arrays for each target half-site.14,15 For the hTERT5SL and 
hTERT5SR target half-sites, we generated ZFPs by includ-
ing a module finger at the Finger 2 and Finger 1 positions 
(respectively) during the creation of the three-fingered cas-
settes used in the stage B2H selections due to the lack of 
coverage provided for some GNN35 and CNN sequences.36 
In addition to the OPEN-based ZFPs made for the hTERT6L 
and hTERT6R target half-sites, we constructed ZFPs by 
assembling module fingers at each ZF position (KW308 
and KW309). For each target half-site, the OPEN protocols 
produced multiple candidate ZFPs, some of which were 
chosen for further screening (Table 1 and Supplementary 
Table S1).
Cloning ZFTFs and ZFNs. To create ZFTFs, chosen candi-
date ZFPs made by the OPEN-based methods were cloned 
into the PRK5.AD-GFZ3 vector provided by Toni Catho-
men to link the VP16 transcriptional activator domain to the 
N-terminus of the ZFP.43 ZFNs were made by cloning many 
of the same ZFPs into the previously characterized GFP-
ZFN2-B2H vector to link a wild-type Fn domain of native 
sequence or codon-optimized to the C-terminus of the 
ZFP.37,44 All cloning was performed using standard molecu-
lar biology techniques.
Screening hTERT ZFTFs for transcriptional activation 
 activity. Approximately 3 kb of the hTERT promoter and 
exon-1 was installed upstream of a GFP reporter. In this 
plasmid construct (pMC6), the endogenous hTERT trans-
lational start codon was mutated from ATG to GTG, but 
the start codon for GFP was preserved. All ZFTFs were 
screened for transcriptional activation activity by cotrans-
fecting 700 ng of ZFTF-expressing plasmid with 100 ng of 
pMC6 using lipofectamine into 1 × 105 HEK293 cells. GFP 
transcription was assayed by measuring %GFP+ cells by 
flow cytometry on day 2 (FACS Calibur; BD Biosciences, 
Franklin Lakes, NJ). pMC6 was cotransfected with a blank 
vector as a negative control. Then, one ZFTF from each tar-
get half-site group (three total) was cotransfected singularly 
in increasing amounts (200–600 ng) and in combination 
(200 ng each) with pMC6 to assay for any dose response. 
In Figure 2b, the x-axis plots cellular autofluorescence as 
“orange” (abscissa) and the y-axis plots the fluorescent 
intensity of GFP expressed by pMC6 as “green”. Fold stimu-
lation of transcriptional activation was calculated as (experi-
mental/background) and error is reported as SD.
SSA assays for screening hTERT ZFN pairs. Based on a 
previously described SSA strategy, reporters were cloned 
by inserting a hTERT full ZFN target site between repeated 
sequences within GFP gene (four total).45 Each of these 
SSA reporters contains a single hTERT target site except 
for the hTERT5 reporter, which also carries the hTERT5C 
site due to the overlapping sequence shared (Table 1). The 
reporter constructs also include the GFP1/2 full ZFN target 
site (5′-ACCATCTTC-ttcaag-GACGACGGC-3′) as a positive 
control and internal standard. These extrachromosomal SSA 
reporter plasmids were used to assay for on-target nuclease 
activity for sets of combinatorial pairs of ZFNs developed for 
each hTERT target site. Briefly, 100 ng of each ZFN-express-
ing plasmid and 20 ng of appropriate reporter plasmid were 
cotransfected into 1 × 105 HEK293 cells using calcium phos-
phate and the GFP1/2 ZFN pair was used as a positive con-
trol. The repair of the GFP gene (after cutting by a pair of 
ZFNs) was measured by %GFP+ cells using flow cytometry 
on day 2. The nuclease activities of all hTERT ZFN pairs 
tested were normalized to the activity of the positive control 
and are reported as a percentage of GFP1/2 ZFN activity. 
Blank vector-treated cell populations were on average 0.1% 
GFP+ and GFP1/2 ZFN-treated cell populations were 0.62, 
0.4, 0.57, 0.52, and 0.33% GFP+ on the hTERT5, hTERT5C, 
hTERT5S, hTERT6, and hTERT6B SSA reporter constructs, 
respectively.
Gene-targeting assay for hTERT6 ZFNs. The hTERT6 
ZFNS were tested for the ability to stimulate homologous 
recombination at a chromosomal target by using a previ-
ously described GFP gene-targeting assay.24 This assay 
uses a GFP reporter that has been mutated by the insertion 
of an hTERT full ZFN target site and an I-SceI recognition 
site as a positive control and internal standard. Within the 
GFP gene, the GFP1/2 full ZFN target site can be found as 
well (see above). This reporter construct was electroporated 
into HEK293 cells and a monoclonal cell line was derived. 
ZFN-expressing plasmids were cotransfected by calcium 
phosphate into the monoclonal cell line in pairs (100 ng 
each) for a combinatorial screen with 300 ng of repair donor 
plasmid. Nuclease-mediated gene-targeting events were 
measured as %GFP+ cells by flow cytometry on day 3. The 
nuclease activities of all ZFN pairs tested were normalized 
to the I-SceI–positive control and are reported as a relative 
percentage of that activity.
Cel-I assay to measure ZFN-induced genomic modification. 
Imperfect repair of a ZFN-induced DSB can result in mis-
matches in the DNA helix that bulge, creating the substrate 
for the Cel-I nuclease. Screening bulk genomic DNA for 
these mismatches at the hTERT locus allowed us to quantify 
percent modification after the application of our ZFNs into 
K562 cells. In brief, 1 × 106 K563 cells were nucleofected 
according to the manufacturer’s instructions (Lonza, Basel, 
Switzerland) and genomic DNA was isolated from cell popu-
lations that had been nucleofected with the hTERT5 ZFNs 
(KW744/KW664) or hTERT6 ZFNs (KW635/KW613) that 
possessed a wild-type Fn domain of native sequence or 
was codon-optimized. Then, the hTERT promoter exon-1 
sequence that contains both the hTERT5 and hTERT6 sites 
was PCR-amplified using the AccuPrime PCR kit (Invitro-
gen, Carlsbad, CA) and a melting temperature of 60 °C. 
When the primers 5′-GCCCGAGTTTCAGGCAGCGCT-
GCGTCCTG-3′ and 5′-TGATGTGCCTGCGCTGCTCTCC-
GCATGTCG-3′ were used, a 373 bp product was formed, 
which we gel-purified from agarose. A total of 200 ng of the 
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purified PCR product was then treated with the Surveyor 
(Cel1) nuclease kit (Transgenomic, Omaha, NE). If the 
genomic hTERT locus had been modified by the hTERT5 or 
hTERT6 ZFNs, then digest products of 248 + 125 bp or 308 
+ 65 bp would appear, respectively. We loaded Surveyor 
digest products onto a 10% acrylamide gel and imaged our 
results using ethidium bromide/ultraviolet. Analysis was per-
formed using ImageJ software and calculations described 
by Miller et al. (2007) after normalizing for nucleofection 
efficiency (~70%).46
Supplementary material
Table S1. Zinc finger DNA-binding domains generated for 
the hTERT5C, hTERT5S, and hTERT6B target sites.
Table S2. Combinatorial screen of hTERT5C ZFN pairs in 
the SSA assay.
Table S3. Combinatorial screen of hTERT5S ZFN pairs in 
the SSA assay.
Table S4. Combinatorial screen of hTERT6B ZFN pairs in 
the SSA assay.
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